Cancer vaccination therapy by using VEGFRs-targeted peptides in the patients who have received trans-arterial chemo-embolization (TACE) against hepatocellular carcinoma -A randomized double blind study
Phase 1
- Conditions
- hepatocellular carcinoma
- Registration Number
- JPRN-UMIN000001731
- Lead Sponsor
- Department of Gastroenterology and Hepatology, Graduate School of Medical Sciences Kumamoto University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Sex
- All
- Target Recruitment
- 30
Inclusion Criteria
Not provided
Exclusion Criteria
1. Patients have more than 10 tumors in the liver before TACE treatment. 2. Patients have major portal vein thrombosis. 3. Patients have extrahepatic metastasis. 4. Patients have uncontrollable associated cancer. 5. Patients have uncontrollable severe infectional diseases. 6. Patients have trauma. 7. Patients who are treated with steroid or immunotherapy during clinical trial. 8. Pregnancy or lactation. 9. Patients who are inappropriate.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method safety
- Secondary Outcome Measures
Name Time Method immunological respose and clinical efficacy